Cardiome Pharma Corp (TSE:COM) (NASDAQ:CRME) Director Arthur Henry Willms acquired 10,000 shares of the business’s stock in a transaction dated Friday, August 25th. The stock was bought at an average cost of C$2.76 per share, with a total value of C$27,600.00.

Cardiome Pharma Corp (TSE COM) traded up 3.66% during midday trading on Friday, hitting $2.83. The stock had a trading volume of 56,853 shares. The stock’s market capitalization is $95.66 million. The stock’s 50-day moving average is $5.11 and its 200-day moving average is $4.72. Cardiome Pharma Corp has a 1-year low of $2.63 and a 1-year high of $6.06.

ILLEGAL ACTIVITY NOTICE: “Cardiome Pharma Corp (COM) Director Arthur Henry Willms Acquires 10,000 Shares” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/08/26/cardiome-pharma-corp-com-director-arthur-henry-willms-acquires-10000-shares.html.

Separately, HC Wainwright reissued a “buy” rating on shares of Cardiome Pharma Corp in a report on Wednesday, May 17th.

Cardiome Pharma Corp Company Profile

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients.

Receive News & Stock Ratings for Cardiome Pharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corp and related stocks with our FREE daily email newsletter.